Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Indian Pharma Companies Face Fresh Product Recalls in US Market
Aurobindo Pharma, Glenmark Pharmaceuticals, and Zydus Lifesciences are currently recalling specific products in the US due to identified manufacturing and labeling issues.
- By Newsdesk
- New Delhi
- Dec 17, 2024
The US subsidiaries of leading Indian pharmaceutical companies have initiated product recalls, once again raising concerns about quality control within India’s pharma sector, a critical player in the global export market. Aurobindo Pharma, Glenmark Pharmaceuticals, and Zydus Lifesciences are currently recalling specific products in the US due to identified manufacturing and labeling issues.
For Aurobindo Pharma and Glenmark, the recalls stem from deviations from the current Good Manufacturing Practices (cGMP) guidelines. Meanwhile, Zydus is withdrawing products because of labeling errors, further underlining the range of challenges faced by Indian drugmakers.
Industry experts caution that repeated quality-related incidents could tarnish India’s reputation in the international pharmaceutical market. Over the past two years, the sector has faced increased scrutiny due to multiple quality issues globally, making recent recalls particularly significant.
However, experts stress that product recalls are a routine and globally accepted part of the pharmaceutical industry. “Recalls should not be viewed negatively. They demonstrate that companies are actively addressing potential issues. Problems can arise not only in manufacturing but also from raw material suppliers or specific production batches,” explained Viranchi Shah, National President of the Indian Drug Manufacturers’ Association (IDMA).
The latest recalls have been categorized as Class II by the US Food and Drug Administration (FDA), indicating that the products could cause temporary or reversible health problems, with a minimal likelihood of severe health risks. This year alone, the FDA has reported 310 instances of drug recalls in the US, reflecting the scale of monitoring and corrective action within the pharmaceutical supply chain.
While the recalls underscore ongoing challenges, they also highlight Indian manufacturers’ commitment to adhering to international safety and quality standards.